Exact Expects FDA Approval For Cologuard Plus In Second Half Of 2024, Featuring 30% Lower False-Positive Rate Compared To Original Cologuard, Improving Cancer Sensitivity And Specificity
Exact Expects FDA Approval For Cologuard Plus In Second Half Of 2024, Featuring 30% Lower False-Positive Rate Compared To Original Cologuard, Improving Cancer Sensitivity And Specificity
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.